- EN
Table GPS-6. Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000
Part (iv) Young adults female (aged 15–34)
| Country | Geographical area | Year | Reference | Age range young adults | Sample size young adults | Cannabis (%) | Cocaine (%) (1) | Amphetamines (%) (2) | Ecstasy (%) (3) | LSD (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Belgium | National | 2008 | (7) | 15–34 | 2550 | 3.6 | : | : | : | : | |
| Bulgaria | National | 2008 | (3) | 15–34 | 2164 | 2.4 | 0.9 | 0.9 | 0.5 | 0.0 | |
| Czech Republic | National | 2011 | (8) | 15–34 | 361 | 4.5 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Denmark | National | 2010 | (6) | 16–34 | 3381 | 3.1 | 0.1 | 0.2 | 0.1 | 0.0 | |
| Germany | National | 2009 | (8) | 18–34 | 3876 | 3.5 | 0.2 | 0.6 | 0.1 | 0.0 | |
| Estonia | National | 2008 | (3) | 15–34 | 545 | 2.7 | 0.3 | 0.0 | 0.3 | 0.0 | |
| Ireland | National | 2010–11 | (6) | 15–34 | : | 1.6 | 0.4 | 0.1 | 0.1 | 0.0 | |
| Greece | National (except Aegean and Ionian Islands) | 2004 | (3) | 15–34 | 2620 | 0.9 | 0.1 | 0.0 | 0.0 | 0.0 | |
| Spain | National | 2011 | (9) | 15–34 | 10507 | 7.0 | 0.7 | 0.3 | 0.4 | : | |
| France | National | 2010 | (7) | 15–34 | 7727 | 5.5 | : | : | : | : | |
| Italy | (4) | National | 2012 | (5) | 18–34 | 4966 | 2.4 | 0.2 | 0.0 | 0.0 | 0.0 |
| Cyprus | National | 2009 | (2) | 15–34 | 1810 | 1.5 | 0.4 | 0.1 | 0.1 | 0.1 | |
| Latvia | National | 2011 | (3) | 15–34 | 2258 | 1.7 | 0.1 | 0.1 | 0.0 | 0.0 | |
| Lithuania | National | 2008 | (2) | 15–34 | 2152 | 1.6 | 0.0 | : | 0.4 | 0.2 | |
| Luxembourg | : | : | : | : | : | : | : | : | : | : | |
| Hungary | National | 2007 | (3) | 18-34 | 1111 | 1.4 | 0.0 | 0.0 | 0.2 | 0.0 | |
| Malta | National | 2001 | (1) | 18–34 | 640 | : | : | : | : | : | |
| Netherlands | (5) | National | 2009 | (4) | 15–34 | : | : | : | : | : | : |
| Austria | National | 2008 | (2) | 15–34 | 2558 | 2.2 | 0.5 | 0.2 | 0.5 | 0.0 | |
| Poland | National | 2010 | (3) | 15–34 | 3201 | 5.1 | 0.8 | 0.9 | 0.3 | 0.0 | |
| Portugal | National | 2007 | (2) | 15–34 | 4765 | 1.0 | 0.2 | 0.1 | 0.2 | 0.0 | |
| Romania | National | 2010 | (3) | 15–34 | 3108 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Slovenia | National | 2007 | (1) | 15–34 | 691 | : | : | : | : | : | |
| Slovakia | National | 2010 | (7) | 15–34 | 1769 | 0.9 | 0.0 | 0.0 | 0.1 | 0.0 | |
| Finland | National | 2010 | (8) | 15–34 | 875 | 1.2 | 0.0 | 0.2 | 0.2 | 0.0 | |
| Sweden | National | 2008 | (5) | 15–34 | 16271 | 0.4 | 0.3 | 0.2 | 0.0 | : | |
| Sweden | National | 2011 | (13) | 16-34 | 2035 | 1.5 | : | : | : | : | |
| United Kingdom | England and Wales | 2011-12 | (15) | 16-34 | 9691 | 4.2 | 1.0 | 0.3 | 0.7 | 0.0 | |
| United Kingdom | Northern Ireland | 2010-11 | (21) | 15-34 | 855 | 1.7 | 0.3 | 0.4 | 0.3 | 0.0 | |
| United Kingdom | Scotland | 2010-11 | (27) | 16–34 | 2432 | 4.3 | 0.9 | 0.4 | 0.7 | 0.0 | |
| United Kingdom | United Kingdom | 2006 | (29) | 16–34 | : | 5.6 | 1.7 | 0.6 | 1.1 | 0.0 | |
| Croatia | National | 2012 | (1) | 15-34 | 1995 | 3.7 | 0.3 | 0.2 | 0.1 | 0.1 | |
| Turkey | National | 2011 | (1) | 15-34 | 4039 | : | : | : | 0.1 | : | |
| Norway | National | 2009 | (3) | 15–34 | 632 | 1.5 | 0.3 | 0.6 | 0.0 | 0.0 |
Notes:
(1) Cocaine, any form.
(2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy.
(3) For Spain: ecstasy and other designer drugs.
(4) The most recent general population survey reported by Italy display a wide variation in results compared with the previous surveys which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.
(5) The most recent General population surveys reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.
Sample sizes refer to the whole age group. Specific sample sizes by gender are not available at the moment but will be collected in the future.
This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey.
In surveys with small sample sizes results should be interpreted with caution.
Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.
For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions.
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Sources:
See Table GPS-0.